CytRx (CYTR) set to begin global phase 3 trial for aldoxorubicin as a second-line treatment for soft tissue sarcoma (STS) after the phase 2 trial demonstrated 80 - 100% superiority of doxorubicin in median progression-free survival (PFS), 6-month PFS and overall response rate.
Under a Special Protocol Assessment from the FDA, the phase 3 trial will target STS patients who have relapsed or are refractory following prior chemotherapy treatment. In January, the FDA approved continued dosing until disease progression.
Two phase trials are underway for assess the safety and efficacy of aldoxorubicin in patients with unresectable glioblastoma multiforme and Kaposi's sarcoma.
Quick assets totaled $38.5M at years end.
The company raised $86M in a secondary offering last month.
Mutual fund ownership has increased from 21 to 25 over the past 4 quarters.